No biomarker
|
Fallopian Tube Cancer
|
No biomarker
|
Fallopian Tube Cancer
|
niraparib Sensitive: A1 - Approval
|
niraparib Sensitive: A1 - Approval
|
No biomarker
|
Fallopian Tube Cancer
|
No biomarker
|
Fallopian Tube Cancer
|
bevacizumab Sensitive: A1 - Approval
|
bevacizumab Sensitive: A1 - Approval
|
No biomarker
|
Fallopian Tube Cancer
|
No biomarker
|
Fallopian Tube Cancer
|
Mvasi (bevacizumab biosimilar) Sensitive: A1 - Approval
|
Mvasi (bevacizumab biosimilar) Sensitive: A1 - Approval
|
No biomarker
|
Fallopian Tube Cancer
|
No biomarker
|
Fallopian Tube Cancer
|
Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval
|
Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval
|
No biomarker
|
Fallopian Tube Cancer
|
No biomarker
|
Fallopian Tube Cancer
|
Onbevzi (bevacizumab biosimilar) Sensitive: A1 - Approval
|
Onbevzi (bevacizumab biosimilar) Sensitive: A1 - Approval
|
BRCA1 mutation
|
Fallopian Tube Cancer
|
BRCA1 mutation
|
Fallopian Tube Cancer
|
rucaparib Sensitive: A1 - Approval
|
rucaparib Sensitive: A1 - Approval
|
BRCA2 mutation
|
Fallopian Tube Cancer
|
BRCA2 mutation
|
Fallopian Tube Cancer
|
rucaparib Sensitive: A1 - Approval
|
rucaparib Sensitive: A1 - Approval
|
No biomarker
|
Fallopian Tube Cancer
|
No biomarker
|
Fallopian Tube Cancer
|
rucaparib Sensitive: A1 - Approval
|
rucaparib Sensitive: A1 - Approval
|
BRCA2 mutation
|
Fallopian Tube Cancer
|
BRCA2 mutation
|
Fallopian Tube Cancer
|
bevacizumab + olaparib Sensitive: A1 - Approval
|
bevacizumab + olaparib Sensitive: A1 - Approval
|
BRCA1 mutation
|
Fallopian Tube Cancer
|
BRCA1 mutation
|
Fallopian Tube Cancer
|
bevacizumab + olaparib Sensitive: A1 - Approval
|
bevacizumab + olaparib Sensitive: A1 - Approval
|
HRD
|
Fallopian Tube Cancer
|
HRD
|
Fallopian Tube Cancer
|
bevacizumab + olaparib Sensitive: A1 - Approval
|
bevacizumab + olaparib Sensitive: A1 - Approval
|
No biomarker
|
Fallopian Tube Cancer
|
No biomarker
|
Fallopian Tube Cancer
|
olaparib Sensitive: A1 - Approval
|
olaparib Sensitive: A1 - Approval
|
BRCA1 mutation
|
Fallopian Tube Cancer
|
BRCA1 mutation
|
Fallopian Tube Cancer
|
niraparib Sensitive: A1 - Approval
|
niraparib Sensitive: A1 - Approval
|
BRCA2 mutation
|
Fallopian Tube Cancer
|
BRCA2 mutation
|
Fallopian Tube Cancer
|
niraparib Sensitive: A1 - Approval
|
niraparib Sensitive: A1 - Approval
|
HRD
|
Fallopian Tube Cancer
|
HRD
|
Fallopian Tube Cancer
|
niraparib Sensitive: A1 - Approval
|
niraparib Sensitive: A1 - Approval
|
BRCA2 mutation
|
Fallopian Tube Cancer
|
BRCA2 mutation
|
Fallopian Tube Cancer
|
olaparib Sensitive: A1 - Approval
|
olaparib Sensitive: A1 - Approval
|
BRCA1 mutation
|
Fallopian Tube Cancer
|
BRCA1 mutation
|
Fallopian Tube Cancer
|
olaparib Sensitive: A1 - Approval
|
olaparib Sensitive: A1 - Approval
|
No biomarker
|
Fallopian Tube Cancer
|
No biomarker
|
Fallopian Tube Cancer
|
carboplatin + micellar paclitaxel Sensitive: A1 - Approval
|
carboplatin + micellar paclitaxel Sensitive: A1 - Approval
|
BRCA1 mutation
|
Fallopian Tube Cancer
|
BRCA1 mutation
|
Fallopian Tube Cancer
|
pamiparib Sensitive: A1 - Approval
|
pamiparib Sensitive: A1 - Approval
|
No biomarker
|
Fallopian Tube Cancer
|
No biomarker
|
Fallopian Tube Cancer
|
Bevax (bevacizumab biosimilar) Sensitive: A1 - Approval
|
Bevax (bevacizumab biosimilar) Sensitive: A1 - Approval
|
BRCA2 mutation
|
Fallopian Tube Cancer
|
BRCA2 mutation
|
Fallopian Tube Cancer
|
pamiparib Sensitive: A1 - Approval
|
pamiparib Sensitive: A1 - Approval
|
No biomarker
|
Fallopian Tube Cancer
|
No biomarker
|
Fallopian Tube Cancer
|
CAPOX Sensitive: A2 - Guideline
|
CAPOX Sensitive: A2 - Guideline
|
No biomarker
|
Fallopian Tube Cancer
|
No biomarker
|
Fallopian Tube Cancer
|
sorafenib Sensitive: A2 - Guideline
|
sorafenib Sensitive: A2 - Guideline
|
No biomarker
|
Fallopian Tube Cancer
|
No biomarker
|
Fallopian Tube Cancer
|
topotecan Sensitive: A2 - Guideline
|
topotecan Sensitive: A2 - Guideline
|
No biomarker
|
Fallopian Tube Cancer
|
No biomarker
|
Fallopian Tube Cancer
|
pegylated liposomal doxorubicin Sensitive: A2 - Guideline
|
pegylated liposomal doxorubicin Sensitive: A2 - Guideline
|
MSI-H/dMMR
|
Fallopian Tube Cancer
|
MSI-H/dMMR
|
Fallopian Tube Cancer
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
NTRK3 fusion
|
Fallopian Tube Cancer
|
NTRK3 fusion
|
Fallopian Tube Cancer
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
Fallopian Tube Cancer
|
NTRK2 fusion
|
Fallopian Tube Cancer
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
NTRK1 fusion
|
Fallopian Tube Cancer
|
NTRK1 fusion
|
Fallopian Tube Cancer
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
NTRK3 fusion
|
Fallopian Tube Cancer
|
NTRK3 fusion
|
Fallopian Tube Cancer
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
Fallopian Tube Cancer
|
NTRK2 fusion
|
Fallopian Tube Cancer
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
NTRK1 fusion
|
Fallopian Tube Cancer
|
NTRK1 fusion
|
Fallopian Tube Cancer
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
No biomarker
|
Fallopian Tube Cancer
|
No biomarker
|
Fallopian Tube Cancer
|
etoposide oral Sensitive: A2 - Guideline
|
etoposide oral Sensitive: A2 - Guideline
|
No biomarker
|
Fallopian Tube Cancer
|
No biomarker
|
Fallopian Tube Cancer
|
trametinib Sensitive: A2 - Guideline
|
trametinib Sensitive: A2 - Guideline
|
No biomarker
|
Fallopian Tube Cancer
|
No biomarker
|
Fallopian Tube Cancer
|
fulvestrant Sensitive: A2 - Guideline
|
fulvestrant Sensitive: A2 - Guideline
|
No biomarker
|
Fallopian Tube Cancer
|
No biomarker
|
Fallopian Tube Cancer
|
cisplatin + irinotecan Sensitive: A2 - Guideline
|
cisplatin + irinotecan Sensitive: A2 - Guideline
|
No biomarker
|
Fallopian Tube Cancer
|
No biomarker
|
Fallopian Tube Cancer
|
albumin-bound paclitaxel Sensitive: A2 - Guideline
|
albumin-bound paclitaxel Sensitive: A2 - Guideline
|
No biomarker
|
Fallopian Tube Cancer
|
No biomarker
|
Fallopian Tube Cancer
|
pazopanib Sensitive: A2 - Guideline
|
pazopanib Sensitive: A2 - Guideline
|
No biomarker
|
Fallopian Tube Cancer
|
No biomarker
|
Fallopian Tube Cancer
|
bevacizumab + niraparib Sensitive: A2 - Guideline
|
bevacizumab + niraparib Sensitive: A2 - Guideline
|
No biomarker
|
Fallopian Tube Cancer
|
No biomarker
|
Fallopian Tube Cancer
|
vinorelbine tartrate Sensitive: A2 - Guideline
|
vinorelbine tartrate Sensitive: A2 - Guideline
|
No biomarker
|
Fallopian Tube Cancer
|
No biomarker
|
Fallopian Tube Cancer
|
pemetrexed Sensitive: A2 - Guideline
|
pemetrexed Sensitive: A2 - Guideline
|
No biomarker
|
Fallopian Tube Cancer
|
No biomarker
|
Fallopian Tube Cancer
|
paclitaxel Sensitive: A2 - Guideline
|
paclitaxel Sensitive: A2 - Guideline
|
No biomarker
|
Fallopian Tube Cancer
|
No biomarker
|
Fallopian Tube Cancer
|
oxaliplatin Sensitive: A2 - Guideline
|
oxaliplatin Sensitive: A2 - Guideline
|
No biomarker
|
Fallopian Tube Cancer
|
No biomarker
|
Fallopian Tube Cancer
|
melphalan Sensitive: A2 - Guideline
|
melphalan Sensitive: A2 - Guideline
|
No biomarker
|
Fallopian Tube Cancer
|
No biomarker
|
Fallopian Tube Cancer
|
irinotecan Sensitive: A2 - Guideline
|
irinotecan Sensitive: A2 - Guideline
|
No biomarker
|
Fallopian Tube Cancer
|
No biomarker
|
Fallopian Tube Cancer
|
ifosfamide Sensitive: A2 - Guideline
|
ifosfamide Sensitive: A2 - Guideline
|
No biomarker
|
Fallopian Tube Cancer
|
No biomarker
|
Fallopian Tube Cancer
|
doxorubicin hydrochloride Sensitive: A2 - Guideline
|
doxorubicin hydrochloride Sensitive: A2 - Guideline
|
No biomarker
|
Fallopian Tube Cancer
|
No biomarker
|
Fallopian Tube Cancer
|
cyclophosphamide Sensitive: A2 - Guideline
|
cyclophosphamide Sensitive: A2 - Guideline
|
No biomarker
|
Fallopian Tube Cancer
|
No biomarker
|
Fallopian Tube Cancer
|
cisplatin Sensitive: A2 - Guideline
|
cisplatin Sensitive: A2 - Guideline
|
No biomarker
|
Fallopian Tube Cancer
|
No biomarker
|
Fallopian Tube Cancer
|
capecitabine Sensitive: A2 - Guideline
|
capecitabine Sensitive: A2 - Guideline
|
No biomarker
|
Fallopian Tube Cancer
|
No biomarker
|
Fallopian Tube Cancer
|
carboplatin + gemcitabine Sensitive: A2 - Guideline
|
carboplatin + gemcitabine Sensitive: A2 - Guideline
|
No biomarker
|
Fallopian Tube Cancer
|
No biomarker
|
Fallopian Tube Cancer
|
cisplatin + paclitaxel Sensitive: A2 - Guideline
|
cisplatin + paclitaxel Sensitive: A2 - Guideline
|
No biomarker
|
Fallopian Tube Cancer
|
No biomarker
|
Fallopian Tube Cancer
|
paclitaxel + ifosfamide Sensitive: A2 - Guideline
|
paclitaxel + ifosfamide Sensitive: A2 - Guideline
|
No biomarker
|
Fallopian Tube Cancer
|
No biomarker
|
Fallopian Tube Cancer
|
cisplatin + ifosfamide Sensitive: A2 - Guideline
|
cisplatin + ifosfamide Sensitive: A2 - Guideline
|
No biomarker
|
Fallopian Tube Cancer
|
No biomarker
|
Fallopian Tube Cancer
|
carboplatin + ifosfamide Sensitive: A2 - Guideline
|
carboplatin + ifosfamide Sensitive: A2 - Guideline
|
No biomarker
|
Fallopian Tube Cancer
|
No biomarker
|
Fallopian Tube Cancer
|
carboplatin Sensitive: A2 - Guideline
|
carboplatin Sensitive: A2 - Guideline
|
No biomarker
|
Fallopian Tube Cancer
|
No biomarker
|
Fallopian Tube Cancer
|
tamoxifen Sensitive: A2 - Guideline
|
tamoxifen Sensitive: A2 - Guideline
|
No biomarker
|
Fallopian Tube Cancer
|
No biomarker
|
Fallopian Tube Cancer
|
leuprolide acetate Sensitive: A2 - Guideline
|
leuprolide acetate Sensitive: A2 - Guideline
|
No biomarker
|
Fallopian Tube Cancer
|
No biomarker
|
Fallopian Tube Cancer
|
exemestane Sensitive: A2 - Guideline
|
exemestane Sensitive: A2 - Guideline
|
No biomarker
|
Fallopian Tube Cancer
|
No biomarker
|
Fallopian Tube Cancer
|
letrozole Sensitive: A2 - Guideline
|
letrozole Sensitive: A2 - Guideline
|
No biomarker
|
Fallopian Tube Cancer
|
No biomarker
|
Fallopian Tube Cancer
|
anastrozole Sensitive: A2 - Guideline
|
anastrozole Sensitive: A2 - Guideline
|
No biomarker
|
Fallopian Tube Cancer
|
No biomarker
|
Fallopian Tube Cancer
|
carboplatin + docetaxel Sensitive: A2 - Guideline
|
carboplatin + docetaxel Sensitive: A2 - Guideline
|
No biomarker
|
Fallopian Tube Cancer
|
No biomarker
|
Fallopian Tube Cancer
|
carboplatin + pegylated liposomal doxorubicin Sensitive: A2 - Guideline
|
carboplatin + pegylated liposomal doxorubicin Sensitive: A2 - Guideline
|
No biomarker
|
Fallopian Tube Cancer
|
No biomarker
|
Fallopian Tube Cancer
|
5-fluorouracil + oxaliplatin Sensitive: A2 - Guideline
|
5-fluorouracil + oxaliplatin Sensitive: A2 - Guideline
|
No biomarker
|
Fallopian Tube Cancer
|
No biomarker
|
Fallopian Tube Cancer
|
carboplatin + paclitaxel Sensitive: A2 - Guideline
|
carboplatin + paclitaxel Sensitive: A2 - Guideline
|
No biomarker
|
Fallopian Tube Cancer
|
No biomarker
|
Fallopian Tube Cancer
|
BEP Sensitive: A2 - Guideline
|
BEP Sensitive: A2 - Guideline
|
No biomarker
|
Fallopian Tube Cancer
|
No biomarker
|
Fallopian Tube Cancer
|
VAC Sensitive: A2 - Guideline
|
VAC Sensitive: A2 - Guideline
|
No biomarker
|
Fallopian Tube Cancer
|
No biomarker
|
Fallopian Tube Cancer
|
EP Sensitive: A2 - Guideline
|
EP Sensitive: A2 - Guideline
|
TMB-H
|
Fallopian Tube Cancer
|
TMB-H
|
Fallopian Tube Cancer
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
No biomarker
|
Fallopian Tube Cancer
|
No biomarker
|
Fallopian Tube Cancer
|
bevacizumab + olaparib Sensitive: A2 - Guideline
|
bevacizumab + olaparib Sensitive: A2 - Guideline
|
No biomarker
|
Fallopian Tube Cancer
|
No biomarker
|
Fallopian Tube Cancer
|
cisplatin + gemcitabine Sensitive: A2 - Guideline
|
cisplatin + gemcitabine Sensitive: A2 - Guideline
|
No biomarker
|
Fallopian Tube Cancer
|
No biomarker
|
Fallopian Tube Cancer
|
OMP-305B83 Sensitive: B - Late Trials
|
OMP-305B83 Sensitive: B - Late Trials
|
No biomarker
|
Fallopian Tube Cancer
|
No biomarker
|
Fallopian Tube Cancer
|
STRO-002 Sensitive: B - Late Trials
|
STRO-002 Sensitive: B - Late Trials
|
PD-L1 expression
|
Fallopian Tube Cancer
|
PD-L1 expression
|
Fallopian Tube Cancer
|
pembrolizumab Sensitive: C1 - Off-label
|
pembrolizumab Sensitive: C1 - Off-label
|
HRD + BRCA2 mutation
|
Fallopian Tube Cancer
|
HRD + BRCA2 mutation
|
Fallopian Tube Cancer
|
niraparib Sensitive: C3 – Early Trials
|
niraparib Sensitive: C3 – Early Trials
|
HRD + BRCA1 mutation
|
Fallopian Tube Cancer
|
HRD + BRCA1 mutation
|
Fallopian Tube Cancer
|
niraparib Sensitive: C3 – Early Trials
|
niraparib Sensitive: C3 – Early Trials
|
TUBB3 expression
|
Fallopian Tube Cancer
|
TUBB3 expression
|
Fallopian Tube Cancer
|
bevacizumab + ixabepilone Resistant: C3 – Early Trials
|
bevacizumab + ixabepilone Resistant: C3 – Early Trials
|